Large Global Phase III Clinical Trial in Metastatic Colorectal Carcinoma (mCRC)
UBC successfully managed a large global phase III clinical trial in patients with mCRC refractory to standard chemotherapies.
The target was to randomize 800 patients in an 18-month period. The trial ran in 113 sites, across 13 countries. This was a full-service contract, with UBC being responsible for all activities related to study execution and analysis.
Read the case study to learn how patient enrollment was completed three months ahead of schedule and database lock three and a half months ahead of schedule.